AC Immune dosed the first patient in Cohort AD4 of the Phase 1b/2 ABATE trial, triggering a $12 million milestone payment from Takeda under their license agreement for ACI-24 anti-Abeta immunotherapy.
Key takeaways
Dosed first patient in Cohort AD4 (prodromal AD) of ongoing Phase 1b/2 ABATE trial, triggering $12 million milestone from Takeda.
ABATE trial assesses ACI-24 safety, tolerability, immunogenicity, and pharmacodynamic effects in prodromal AD and Down syndrome patients.
Cohorts AD1-AD3 (74 patients) show ACI-24 generally safe, well-tolerated with anti-Abeta antibody responses; 12-month data expected Q2 2026.
Cohort AD4 starts with 36 patients (12-month treatment + 6-month follow-up), potential expansion to ~112 patients.
Takeda agreement includes $100M upfront received, up to ~$2.1B in milestones, and tiered double-digit royalties on net sales.